Skip to main content

Advertisement

Table 2 Incidence of clinically significant deficits in QOL for each cohort

From: Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales

Cohorts   QOL score on 0–10 scale N (%)  
  Missing <=5 >5 to <8 8-10 Total
Advanced cancer 7 25 (21%) 30 (25%) 65 (54%) 120
Brain cancer 0 8 (31%) 11 (42%) 7 (27%) 26
Breast cancer 0 27 (9%) 94 (32%) 175 (59%) 296
Clinical trial lung cancer 0 236 (20%) 350 (30%) 569 (49%) 1155
Colon cancer pts-2 wks post surgery (Colectomy) 63 67 (17%) 118 (30%) 203 (52%) 388
Colon cancer pts-pre surgery (Colectomy) 48 58 (14%) 85 (21%) 260 (65%) 403
GI cancer 0 287 (12%) 682 (28%) 1440 (60%) 2409
GU cancer 0 14 (8%) 41 (23%) 125 (69%) 180
Gynecologic cancer 0 14 (12%) 35 (30%) 68 (58%) 117
Head and neck cancer 0 54 (21%) 78 (31%) 122 (48%) 254
Hematologic cancer 0 4 (13%) 13 (41%) 15 (47%) 32
Lymphatic cancer 0 2 (25%) 1 (13%) 5 (63%) 8
Multiple site cancer 0 0 (0%) 5 (36%) 9 (64%) 14
Musculoskeletal site cancer 0 6 (33%) 5 (28%) 7 (39%) 18
Neurologic cancer 0 25 (12%) 75 (35%) 114 (53%) 214
Other cancer 0 8 (15%) 8 (15%) 36 (69%) 52
Lung cancer- Mayo study 0 137 (26%) 143 (27%) 249 (47%) 529
Lung cancer- Mayo study 6 months post diagnosis 0 326 (23%) 426 (30%) 657 (47%) 1409
Skin cancer 0 0 (0%) 4 (57%) 3 (43%) 7
Unknown site cancer 0 10 (34%) 9 (31%) 10 (34%) 29
Healthy NCCTG volunteers 0 1 (2%) 12 (22%) 41 (76%) 54
Hospice caregivers 4 9 (17%) 23 (43%) 21 (40%) 53
Hospice 5 22 (42%) 23 (44%) 7 (13%) 52
Minnesota medical students 2 84 (15%) 202 (37%) 257 (47%) 543
Mayo physicians 5 58 (13%) 174 (38%) 228 (50%) 460
Mayo residents 0 83 (28%) 125 (42%) 87 (29%) 295
Advanced cancer –psychosocial study 0 10 (23%) 24 (55%) 10 (23%) 44
  1. NCCTG, North central chapter treatment group.